RxDoctor Payments Data

Fernando Diaz, MD

Endocrinology, Diabetes & Metabolism · Hollywood, FLNPI 1174699870

Payments from drug & device makers

$256in general payments, 2019–2025

Across 13 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$124
  • Recordati_rare_diseases_inc.$25
  • AstraZeneca$25
  • Abbott$22
  • Novo Nordisk$16
  • Ascend Therapeutics US, LLC$16
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$22889%
  • Education$125%
  • Gifts$166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$124
Recordati_rare_diseases_inc.1$25
AstraZeneca1$25
Abbott1$22
Novo Nordisk1$16
Ascend Therapeutics US, LLC1$16
Amarin Pharma, Inc.1$16
Xeris Pharmaceuticals, Inc.1$12

How this compares

$256 in reported general payments places this provider in the 15th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$157,537
Medicare patients
230
Services billed
1,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$64,703
FarxigaDapagliflozin Propanediol45$52,891
MounjaroTirzepatide42$39,465
JardianceEmpagliflozin34$35,845
TrulicityDulaglutide23$24,748
TradjentaLinagliptin15$18,378
Tresiba Flextouch U-100Insulin Degludec32$17,469
VascepaIcosapent Ethyl22$16,485
Tresiba Flextouch U-200Insulin Degludec14$14,123
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,332
Novolog FlexpenInsulin Aspart22$7,667
Humalog Kwikpen U-100Insulin Lispro23$6,200
Nano 2nd Gen Pen NeedlePen Needle, Diabetic32$4,585
SynthroidLevothyroxine Sodium46$3,938
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$64,70335 claims
Lilly USA, LLCMounjaro, Trulicity$124$64,21265 claims
AstraZenecaFarxiga$25$52,89145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →